drugset / Trial / NCT00264381

Management of Superficial Thrombophlebitis

NCT00264381

Phase 4 Completed 72 enrolled University of Oklahoma Pfizer · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial thrombophlebitis (STP).

Timeline

Start
2002-10
Primary completion
2009-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dalteparin sodium Other / unclassified 10000 iu Subcutaneous

Indications